4 ms·

Thanks for the comparison against 23 and me but I’d be interested in how you plan to differ from Invitae/Fulgent/Myraid aside from the D2C aspects.

• astroH 7y ago
  Great question. Right now the major difference is the D2C (patient-initiated, physician-ordered) aspect. Invitae is starting to offer this to some extent but they mainly seem focused on cardiovascular and cancer. Unlike those companies, we don't consider ourselves a testing company. For most patients in the rare disease space, understanding the underlying genetic cause is really only the first step in the process and then most need tons of help navigating the healthcare space afterwards. We started with the test, mainly because of the access and affordability issue patients were having. Many of our patients have requested tools for longitudinal phenotypic data collection, connections with all of the relevant advocacy groups, further genetic counselling, efficient ways to test family members, and detailed, patient-readable information content about their variant. We try to provide everything these patients need (aside from medical advice of course) as the healthcare system isn't currently set up to help rare disease patients.